ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM
Abstract Number: 1452
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
10:30AM-12:30PM
Abstract Number: 1158
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1167
Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1458
Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
10:30AM-12:30PM
Abstract Number: 1126
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I
10:30AM-12:30PM
Abstract Number: 1284
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
(1272–1305) Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1189
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1305
Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study
(1272–1305) Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1647
Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
(1633–1649) ARP Posters II: ARP Epidemiology & Public Health
10:30AM-12:30PM
Abstract Number: 1575
Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1181
Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1020
Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
(1007–1037) Epidemiology & Public Health Poster II
10:30AM-12:30PM
Abstract Number: 1277
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
(1272–1305) Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1605
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
(1592–1611) Vasculitis – ANCA-Associated Poster II
10:30AM-12:30PM
Abstract Number: 1054
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
(1038–1054) Health Services Research Poster II
  • «Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 58
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology